ReP USP - Resultado da busca

Artigo de periodico-carta/editorial
Performance of the Cockcroft-Gault, Modification of Diet in Renal Disease, and new Chronic Kidney Disease Epidemiology Collaboration equations without race in older acute medical patients reply (2022)
Silva, Veronica T. Costa e; Inker, Lesley A; Burdmann, Emmanuel de Almeida ; Levey, Andrew S
Source: Kidney international. Unidade: FM
Subjects: DOENÇA CRÔNICA, NEFROPATIAS, DIETOTERAPIA, EPIDEMIOLOGIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVA, Veronica T. Costa e et al. Performance of the Cockcroft-Gault, Modification of Diet in Renal Disease, and new Chronic Kidney Disease Epidemiology Collaboration equations without race in older acute medical patients reply. Kidney international. New York: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1016/j.kint.2022.02.017. Acesso em: 16 nov. 2024. , 2022
APA
Silva, V. T. C. e, Inker, L. A., Burdmann, E. de A., & Levey, A. S. (2022). Performance of the Cockcroft-Gault, Modification of Diet in Renal Disease, and new Chronic Kidney Disease Epidemiology Collaboration equations without race in older acute medical patients reply. Kidney international. New York: Faculdade de Medicina, Universidade de São Paulo. doi:10.1016/j.kint.2022.02.017
NLM
Silva VTC e, Inker LA, Burdmann E de A, Levey AS. Performance of the Cockcroft-Gault, Modification of Diet in Renal Disease, and new Chronic Kidney Disease Epidemiology Collaboration equations without race in older acute medical patients reply [Internet]. Kidney international. 2022 ; 101( 5): 1088-1089.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.kint.2022.02.017
Vancouver
Silva VTC e, Inker LA, Burdmann E de A, Levey AS. Performance of the Cockcroft-Gault, Modification of Diet in Renal Disease, and new Chronic Kidney Disease Epidemiology Collaboration equations without race in older acute medical patients reply [Internet]. Kidney international. 2022 ; 101( 5): 1088-1089.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.kint.2022.02.017
Artigo de periodico
Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017 (2020)
Bikbov, Boris; Purcell, Carrie; Levey, Andrew S; Smith, Mari; Abdoli, Amir; Abebe, Molla; Adebayo, Oladimeji M; Benseñor, Isabela Judith Martins ; Lotufo, Paulo Andrade ; Santos, Itamar de Souza
Source: Lancet. Unidade: FM
Subjects: INFERÊNCIA BAYESIANA, CAUSA DA MORTE, NEFROPATIAS, MORTALIDADE, INSUFICIÊNCIA RENAL CRÔNICA, AVALIAÇÃO DE RISCO, ÁFRICA, ÁSIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BIKBOV, Boris et al. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, v. 395, n. 10225, p. 709-733, 2020Tradução . . Disponível em: https://doi.org/10.1016/S0140-6736(20)30045-3. Acesso em: 16 nov. 2024.
APA
Bikbov, B., Purcell, C., Levey, A. S., Smith, M., Abdoli, A., Abebe, M., et al. (2020). Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, 395( 10225), 709-733. doi:10.1016/S0140-6736(20)30045-3
NLM
Bikbov B, Purcell C, Levey AS, Smith M, Abdoli A, Abebe M, Adebayo OM, Benseñor IJM, Lotufo PA, Santos I de S. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017 [Internet]. Lancet. 2020 ; 395( 10225): 709-733.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/S0140-6736(20)30045-3
Vancouver
Bikbov B, Purcell C, Levey AS, Smith M, Abdoli A, Abebe M, Adebayo OM, Benseñor IJM, Lotufo PA, Santos I de S. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017 [Internet]. Lancet. 2020 ; 395( 10225): 709-733.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/S0140-6736(20)30045-3
Artigo de periodico
Treatment of anemia with darbepoetin prior to dialysis initiation and clinical outcomes: analyses from the trial to reduce cardiovascular events with aranesp therapy (TREAT) (2019)
Causland, Finnian R. Mc; Claggett, Brian; Burdmann, Emmanuel de Almeida; Chertow, Glenn M; Cooper, Mark E; Eckardt, Kai-Uwe; Ivanovich, Peter; Levey, Andrew S; Lewis, Eldrin F; Mcgill, Janet B
Source: American journal of kidney diseases. Unidade: FM
Subjects: ANEMIA, ERITROPOIETINA, HEMODIÁLISE, DOENÇAS CARDIOVASCULARES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CAUSLAND, Finnian R. Mc et al. Treatment of anemia with darbepoetin prior to dialysis initiation and clinical outcomes: analyses from the trial to reduce cardiovascular events with aranesp therapy (TREAT). American journal of kidney diseases, v. 73, n. 3, p. 309-315, 2019Tradução . . Disponível em: https://doi.org/10.1053/j.ajkd.2018.10.006. Acesso em: 16 nov. 2024.
APA
Causland, F. R. M., Claggett, B., Burdmann, E. de A., Chertow, G. M., Cooper, M. E., Eckardt, K. -U., et al. (2019). Treatment of anemia with darbepoetin prior to dialysis initiation and clinical outcomes: analyses from the trial to reduce cardiovascular events with aranesp therapy (TREAT). American journal of kidney diseases, 73( 3), 309-315. doi:10.1053/j.ajkd.2018.10.006
NLM
Causland FRM, Claggett B, Burdmann E de A, Chertow GM, Cooper ME, Eckardt K-U, Ivanovich P, Levey AS, Lewis EF, Mcgill JB. Treatment of anemia with darbepoetin prior to dialysis initiation and clinical outcomes: analyses from the trial to reduce cardiovascular events with aranesp therapy (TREAT) [Internet]. American journal of kidney diseases. 2019 ; 73( 3): 309-315.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1053/j.ajkd.2018.10.006
Vancouver
Causland FRM, Claggett B, Burdmann E de A, Chertow GM, Cooper ME, Eckardt K-U, Ivanovich P, Levey AS, Lewis EF, Mcgill JB. Treatment of anemia with darbepoetin prior to dialysis initiation and clinical outcomes: analyses from the trial to reduce cardiovascular events with aranesp therapy (TREAT) [Internet]. American journal of kidney diseases. 2019 ; 73( 3): 309-315.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1053/j.ajkd.2018.10.006
Artigo de periodico
Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial (2017)
Causland, Finnian R. Mc; Claggett, Brian; Pfeffer, Marc A; Burdmann, Emmanuel de Almeida; Eckardt, Kai-Uwe; Levey, Andrew S; McMurray, John J. V; Remuzzi, Giuseppe; Singh, Ajay K; Solomon, Scott D; Toto, Robert D; Parfrey, Patrick
Source: American journal of nephrology. Unidade: FM
Subjects: HEMOGLOBINAS, DOENÇAS CARDIOVASCULARES, INSUFICIÊNCIA RENAL CRÔNICA, DIABETES MELLITUS, FÁRMACOS DO SANGUE E SISTEMA HEMATOPOÉTICO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CAUSLAND, Finnian R. Mc et al. Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial. American journal of nephrology, v. 46, n. 6, p. 488-497, 2017Tradução . . Disponível em: https://doi.org/10.1159/000485326. Acesso em: 16 nov. 2024.
APA
Causland, F. R. M., Claggett, B., Pfeffer, M. A., Burdmann, E. de A., Eckardt, K. -U., Levey, A. S., et al. (2017). Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial. American journal of nephrology, 46( 6), 488-497. doi:10.1159/000485326
NLM
Causland FRM, Claggett B, Pfeffer MA, Burdmann E de A, Eckardt K-U, Levey AS, McMurray JJV, Remuzzi G, Singh AK, Solomon SD, Toto RD, Parfrey P. Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial [Internet]. American journal of nephrology. 2017 ; 46( 6): 488-497.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1159/000485326
Vancouver
Causland FRM, Claggett B, Pfeffer MA, Burdmann E de A, Eckardt K-U, Levey AS, McMurray JJV, Remuzzi G, Singh AK, Solomon SD, Toto RD, Parfrey P. Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial [Internet]. American journal of nephrology. 2017 ; 46( 6): 488-497.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1159/000485326

USP Schools

ReP

Filtros

Authors

Subjects